CORRECTION Open Access

## Correction to: Musashi2 promotes EGFinduced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling



Weiwei Sheng<sup>1†</sup>, Xiaoyang Shi<sup>1†</sup>, Yiheng Lin<sup>1</sup>, Jingtong Tang<sup>1</sup>, Chao Jia<sup>1</sup>, Rongxian Cao<sup>2</sup>, Jian Sun<sup>1</sup>, Guosen Wang<sup>3</sup>, Lei Zhou<sup>4</sup> and Ming Dong<sup>1\*</sup>

Correction to: J Exp Clin Cancer Res 39, 16 (2020) https://doi.org/10.1186/s13046-020-1521-4

Following publication of the original article [1], the authors identified some minor errors in image-typesetting in Figs. 2 and 3; specifically in Fig. 2a, and Fig. 3b and Fig. 3d (corrected labels beneath the quantitative histograms). The correct figure is given below. All correction had no any effect to the final conclusion.

## **Author details**

<sup>1</sup>Department of Gastrointestinal Surgery, the First Hospital, China Medical University, Shenyang 110001, China. <sup>2</sup>Department of General Surgery, the People's Hospital of Liaoning province, Shenyang 110034, China. <sup>3</sup>Department of General Surgery, the First Hospital of Nanchang University, NanChang 330006, China. <sup>4</sup>Department of General Surgery, the Central Hospital of JingZhou City, JingZhou 434020, China.

Published online: 24 August 2020

## Reference

 Sheng W, et al. Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. J Exp Clin Cancer Res. 2020;39:16. https://doi. org/10.1186/s13046-020-1521-4.

The original article can be found online at https://doi.org/10.1186/s13046-020-1521-4.

Full list of author information is available at the end of the article




© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.


<sup>\*</sup> Correspondence: dongming@cmu.edu.cn

<sup>&</sup>lt;sup>†</sup>Weiwei Sheng and Xiaoyang Shi contributed equally to this work.

<sup>&</sup>lt;sup>1</sup>Department of Gastrointestinal Surgery, the First Hospital, China Medical University, Shenyang 110001, China



**Fig. 2** Cell morphology in sg1-MSI2, sg2-MSI2 and scramble transfected AsPC-1 and BxPC-3 cells with or without EGF (50 ng/ml) treatment. **a** and **b** Under EGF treatment, the fibroblastoid-like phenotype in AsPC-1 (**a**) and BxPC-3 (**b**) cells in scramble, sg1-MSI2 and sg2-MSI2 groups



**Fig. 3** MSI2 silencing inhibited EGF-induced Cell invasion and migration in PC cells. **a** and **b** Cell invasion (**a**) and migration (**b**) in sg1-MSI2, sg2-MSI2 and scramble transfected AsPC-1 cells with or without EGF (50 ng/ml) treatment. **c** and **d** Cell invasion (**c**) and migration (**d**) in sg1-MSI2, sg2-MSI2 and scramble transfected BxPC-3 cells with or without EGF (50 ng/ml) treatment. Bars indicate ± S.E.\*, P < 0.05; \*\*, P < 0.01 compared with the control